Search Results1-7 of  7

  • MATSUOKA Nobushige ID: 9000001845609

    Pfizer Global R & D, Tokyo Laboratories, Statistical and Clinical Programming, Pfizer Japan Inc. (2006 from CiNii)

    Articles in CiNii:1

    • Meta-analysis and Publication Bias in Medical Research (2006)
  • MATSUOKA Nobushige ID: 9000001976505

    Pfizer Global R & D, Tokyo Laboratories, Statistical and Clinical Programming, Pfizer Japan Inc. (2007 from CiNii)

    Articles in CiNii:1

    • A Practical Method Adjusting for Publication Bias in Meta-analysis Based on p-value (2007)
  • MATSUOKA Nobushige ID: 9000018785717

    Department of Management Science, Graduate School of Engineering, Tokyo University of Science (2011 from CiNii)

    Articles in CiNii:1

    • Improvement of Statistical Power to Detect Publication Bias in Meta-analysis Using the Clinical Trial Registration System (2011)
  • Matsuoka Nobushige ID: 9000014660679

    Pfizer Japan Inc. (2014 from CiNii)

    Articles in CiNii:2

    • 中間データから推定した治療効果が症例数再設定に及ぼす影響(セッション1A) (2009)
    • A Bayesian method to measure predictive performance of a model in a different population from that used to develop the model in clinical development for pediatric or rare diseases (2014)
  • Matsuoka Nobushige ID: 9000292186751

    Clinical Statistics, Development Japan, Pfizer Japan (2015 from CiNii)

    Articles in CiNii:1

    • Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study) (2015)
  • Matsuoka Nobushige ID: 9000309183331

    Articles in CiNii:1

    • CORRIGENDUM: Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study) (2015)
  • Matsuoka Nobushige ID: 9000367055968

    Development Japan, Pfizer Japan Inc. (2017 from CiNii)

    Articles in CiNii:1

    • Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive ― Results From a Randomized, Placebo-Controlled, Dose-Ranging Study ― (2017)
Page Top